The total return over the past 12 months is -54.79% vs. +16.94% for the S&P 500. So far it's up -20.80% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (54.79%) | (48.23%) | (63.30%) | N/A | N/A | N/A |
| Total Return CAGR | (54.79%) | (48.23%) | (63.30%) | N/A | N/A | N/A |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aprea Therapeutics, Inc. (APRE)
| Year | Start price | End price | APRE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.85 | $0.68 | (20.80%) | +14.51% | (35.31%) |
| 2025 | $3.29 | $0.85 | (74.07%) | +17.72% | (91.79%) |
| 2024 | $4.70 | $3.29 | (30.00%) | +24.89% | (54.89%) |
| 2023 | $6.62 | $4.70 | (29.00%) | +26.19% | (55.19%) |
| 2022 | $57.40 | $6.62 | (88.47%) | (18.17%) | (70.30%) |
| 2021 | $98.40 | $57.40 | (41.67%) | +28.74% | (70.41%) |
| 2020 | $917.80 | $98.40 | (89.28%) | +18.37% | (107.65%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
